Modern Retina articleshttps://www.modernretina.com/newsModern Retina articles© 2026 MJH Life Sciences™ and Modern Retina. All rights reserved.Sat, 30 May 2026 10:06:54 +00005en-us14447https://www.modernretina.com/newshttps://www.modernretina.com/logo.webphttps://www.modernretina.com/view/q-a-using-natural-images-for-the-evaluation-of-distance-image-quality-in-iolshttps://www.modernretina.com/view/q-a-using-natural-images-for-the-evaluation-of-distance-image-quality-in-iols<![CDATA[Aixa Alarcon, PhD, and colleagues reported natural image analysis may better predict real-world visual performance of premium intraocular lenses than traditional single-frequency MTF testing, while also capturing the impact of dysphotopsias and residual astigmatism.]]>Fri, 29 May 2026 15:56:26 GMTModern RetinausModern Retina Articleshttps://www.modernretina.com/view/uveai-automated-fluorescein-angiography-scoring-for-retinal-inflammation-in-uveitishttps://www.modernretina.com/view/uveai-automated-fluorescein-angiography-scoring-for-retinal-inflammation-in-uveitis<![CDATA[A modular AI system comprising six transformer models achieves near-expert concordance with an ASUWOG-aligned composite inflammation score]]>Fri, 29 May 2026 04:00:00 GMTModern RetinausModern Retina Articleshttps://www.modernretina.com/view/rwc-2026-rvo-systemic-vascular-healthhttps://www.modernretina.com/view/rwc-2026-rvo-systemic-vascular-health<![CDATA[In this interview from the 2026 Retina World Congress, Katherine Talcott, MD underscores that retinal vein occlusions (RVOs) should prompt retina specialists to look beyond the eye and ensure patients are connected to primary care and cardiology. She highlights the importance of systemic risk factor management and interdisciplinary coordination as essential components of comprehensive RVO care.]]>Thu, 28 May 2026 19:00:00 GMTModern RetinausModern Retina Articleshttps://www.modernretina.com/view/geographic-atrophy-topography-what-the-central-2-5-mm-region-revealshttps://www.modernretina.com/view/geographic-atrophy-topography-what-the-central-2-5-mm-region-reveals<![CDATA[Findings from an 856-patient analysis suggest that evaluating GA topography beyond foveal involvement may better capture patient-reported functional impairment.]]>Thu, 28 May 2026 12:30:00 GMTModern RetinausModern Retina Articleshttps://www.modernretina.com/view/fda-grants-appeal-for-bevacizumab-vikg-bla-in-neovascular-amdhttps://www.modernretina.com/view/fda-grants-appeal-for-bevacizumab-vikg-bla-in-neovascular-amd<![CDATA[The FDA's OND found substantial evidence of effectiveness for bevacizumab-vikg in nAMD, clearing the way for a BLA resubmission in June 2026 and a decision expected within 60 days.]]>Thu, 28 May 2026 10:00:00 GMTModern RetinausModern Retina Articleshttps://www.modernretina.com/view/preclinical-study-explores-contact-lens-based-neuromodulation-for-depressionhttps://www.modernretina.com/view/preclinical-study-explores-contact-lens-based-neuromodulation-for-depression<![CDATA[The device, described in a new study, uses a technique called temporal interference-based transcorneal electrical stimulation, or TI-TES.]]>Wed, 27 May 2026 19:04:35 GMTModern RetinausModern Retina Articleshttps://www.modernretina.com/view/mactel-masquerades-how-to-spot-what-others-misshttps://www.modernretina.com/view/mactel-masquerades-how-to-spot-what-others-miss<![CDATA[Multimodal imaging, OCT biomarkers, and the case for early diagnosis as treatment options emerge for macular telangiectasia.]]>Tue, 26 May 2026 18:00:00 GMTModern RetinausModern Retina Articleshttps://www.modernretina.com/view/qa102-data-suggest-signal-in-intermediate-dry-amd-but-insignificant-drusen-volume-changehttps://www.modernretina.com/view/qa102-data-suggest-signal-in-intermediate-dry-amd-but-insignificant-drusen-volume-change<![CDATA[Oral QA102 shows imaging signals slowing drusen and GA progression in intermediate dry AMD at ARVO 2026, despite missing its primary end point.]]>Tue, 26 May 2026 13:36:48 GMTModern RetinausModern Retina Articleshttps://www.modernretina.com/view/no-smoking-gun-oct-biomarker-found-for-dme-outcomes-insights-from-protocol-thttps://www.modernretina.com/view/no-smoking-gun-oct-biomarker-found-for-dme-outcomes-insights-from-protocol-t<![CDATA[At ARVO 2026, Michael Ip, MD, presented findings from a large-scale analysis of OCT biomarkers in patients with diabetic macular edema (DME), leveraging the robust DRCR Retina Network Protocol T dataset.]]>Tue, 26 May 2026 10:00:00 GMTModern RetinausModern Retina Articleshttps://www.modernretina.com/view/avacincaptad-pegol-analysis-links-ga-treatment-to-preserved-driving-visionhttps://www.modernretina.com/view/avacincaptad-pegol-analysis-links-ga-treatment-to-preserved-driving-vision<![CDATA[Avacincaptad pegol may help preserve driving-related vision in geographic atrophy, but post hoc data did not reach statistical significance.]]>Mon, 25 May 2026 10:00:00 GMTModern RetinausModern Retina Articleshttps://www.modernretina.com/view/tinlarebant-earns-swiss-orphan-drug-status-for-stargardt-diseasehttps://www.modernretina.com/view/tinlarebant-earns-swiss-orphan-drug-status-for-stargardt-disease<![CDATA[Swiss regulator backs tinlarebant for Stargardt as DRAGON phase 3 shows slower retinal atrophy, bringing first treatment closer to patients.]]>Sat, 23 May 2026 16:44:00 GMTModern RetinausModern Retina Articleshttps://www.modernretina.com/view/biogen-completes-acquisition-of-apellis-pharmaceuticalshttps://www.modernretina.com/view/biogen-completes-acquisition-of-apellis-pharmaceuticals<![CDATA[Biogen buys Apellis, taking over Syfovre for geographic atrophy—what it means for GA care, trial data, safety signals, and future formulations.]]>Fri, 22 May 2026 18:16:28 GMTModern RetinausModern Retina Articleshttps://www.modernretina.com/view/intracortical-visual-prosthesis-a-new-chapter-in-advancing-visual-restorationhttps://www.modernretina.com/view/intracortical-visual-prosthesis-a-new-chapter-in-advancing-visual-restoration<![CDATA[Wireless brain implant taps visual cortex to deliver artificial sight, marking third successful surgery and recruiting volunteers for trials.]]>Thu, 21 May 2026 12:00:00 GMTModern RetinausModern Retina Articleshttps://www.modernretina.com/view/retina-world-congress-2026-rethinking-macular-hole-surgery-without-gas-tamponadehttps://www.modernretina.com/view/retina-world-congress-2026-rethinking-macular-hole-surgery-without-gas-tamponade<![CDATA[Siegfried G. Priglinger, MD, FEBO, weighs in on the emerging rationale for gas-free, position-free macular hole surgery using an ILM flap.]]>Sun, 17 May 2026 04:00:00 GMTModern RetinausModern Retina Articleshttps://www.modernretina.com/view/retina-world-congress-2026-identifying-real-world-durability-gaps-in-wet-amd-treatmenthttps://www.modernretina.com/view/retina-world-congress-2026-identifying-real-world-durability-gaps-in-wet-amd-treatment<![CDATA[Patricio G. Schlottmann, MD, examines why injection frequency drives treatment failure in wet AMD and the particular challenges facing patients in Latin America.]]>Sat, 16 May 2026 12:00:00 GMTModern RetinausModern Retina Articleshttps://www.modernretina.com/view/can-vibration-reduce-pain-during-intravitreal-injectionshttps://www.modernretina.com/view/can-vibration-reduce-pain-during-intravitreal-injections<![CDATA[Victor M. Villegas, MD, discusses supraorbital vibration as an adjunct to topical anesthesia in a high-volume retina practice.]]>Sat, 16 May 2026 04:00:00 GMTModern RetinausModern Retina Articleshttps://www.modernretina.com/view/sunir-j-garg-md-facs-on-preventing-occupational-injury-in-retina-practicehttps://www.modernretina.com/view/sunir-j-garg-md-facs-on-preventing-occupational-injury-in-retina-practice<![CDATA[Posture, operating room setup, and small workflow adjustments can reduce cumulative neck and back strain over time.]]>Fri, 15 May 2026 22:00:00 GMTModern RetinausModern Retina Articleshttps://www.modernretina.com/view/diagnosing-macular-telangiectasia-in-a-field-of-mimickershttps://www.modernretina.com/view/diagnosing-macular-telangiectasia-in-a-field-of-mimickers<![CDATA[Jay Chhablani, MD, on multimodal imaging, OCT biomarkers, and the importance of early diagnosis as treatment options emerge]]>Fri, 15 May 2026 19:00:00 GMTModern RetinausModern Retina Articleshttps://www.modernretina.com/view/retina-world-congress-2026-the-case-for-earlier-surgical-intervention-in-diabetic-macular-edemahttps://www.modernretina.com/view/retina-world-congress-2026-the-case-for-earlier-surgical-intervention-in-diabetic-macular-edema<![CDATA[Matias Iglicki, MD, PhD, discusses why internal limiting membrane peeling deserves greater consideration in carefully selected patients with DME.]]>Fri, 15 May 2026 04:00:00 GMTModern RetinausModern Retina Articleshttps://www.modernretina.com/view/retina-world-congress-2026-uveitis-risk-rises-as-immune-checkpoint-inhibitor-use-expandshttps://www.modernretina.com/view/retina-world-congress-2026-uveitis-risk-rises-as-immune-checkpoint-inhibitor-use-expands<![CDATA[Charlie Zhang, MD, reflects on the rising incidence, diagnostic challenges, and multidisciplinary management of immune checkpoint inhibitor–associated uveitis.]]>Thu, 14 May 2026 19:00:00 GMTModern RetinausModern Retina Articleshttps://www.modernretina.com/view/laru-zova-sustains-visual-function-improvements-at-12-months-in-xlrp-gene-therapy-trialhttps://www.modernretina.com/view/laru-zova-sustains-visual-function-improvements-at-12-months-in-xlrp-gene-therapy-trial<![CDATA[Data presented at ARVO 2026 show that high-dose gene therapy boosts central retinal sensitivity in X-linked retinitis pigmentosa, with the phase 3 VISTA study fully enrolled.]]>Wed, 13 May 2026 17:06:36 GMTModern RetinausModern Retina Articleshttps://www.modernretina.com/view/navigating-the-ocular-risks-of-facial-fillers-with-jennifer-murdock-mdhttps://www.modernretina.com/view/navigating-the-ocular-risks-of-facial-fillers-with-jennifer-murdock-md<![CDATA[In the latest episode of The Retina TL;DR with Dr. Weng, host Christina Y. Weng, MD, MBA, FASRS, talks with Dr. Murdock about how the rise of "Ozempic face" has placed aesthetic injectables at the intersection of oculoplastics and retina.]]>Mon, 11 May 2026 21:00:00 GMTModern RetinausModern Retina Articleshttps://www.modernretina.com/view/beyond-anti-vegf-the-next-wave-in-retinal-therapyhttps://www.modernretina.com/view/beyond-anti-vegf-the-next-wave-in-retinal-therapy<![CDATA[New pathways are reshaping the management of retinal disease.]]>Mon, 04 May 2026 18:00:00 GMTModern RetinausModern Retina Articleshttps://www.modernretina.com/view/condor-clinical-trial-brolucizumab-superior-to-panretinal-photocoagulation-for-proliferative-diabetic-retinopathyhttps://www.modernretina.com/view/condor-clinical-trial-brolucizumab-superior-to-panretinal-photocoagulation-for-proliferative-diabetic-retinopathy<![CDATA[Phase 3 data show brolucizumab outperforms laser for PDR vision preservation, with fewer adverse events—while monitoring inflammation risk.]]>Wed, 29 Apr 2026 10:01:00 GMTModern RetinausModern Retina Articleshttps://www.modernretina.com/view/belite-bio-initiates-rolling-nda-submission-for-tinlarebant-in-stargardt-disease-type-1https://www.modernretina.com/view/belite-bio-initiates-rolling-nda-submission-for-tinlarebant-in-stargardt-disease-type-1<![CDATA[According to the company, the NDA submission is supported by data from the phase 3 DRAGON trial.]]>Tue, 28 Apr 2026 14:33:30 GMTModern RetinausModern Retina Articleshttps://www.modernretina.com/view/additional-sol-1-analyses-show-delayed-csft-worsening-with-axpaxlihttps://www.modernretina.com/view/additional-sol-1-analyses-show-delayed-csft-worsening-with-axpaxli<![CDATA[SOL-1 data show AXPAXLI extends wet AMD control, delaying fluid rebound and reducing rescue injections while sustaining vision through 52 weeks.]]>Mon, 27 Apr 2026 10:01:00 GMTModern RetinausModern Retina Articleshttps://www.modernretina.com/view/eichenbaum-acorns-paying-it-forward-with-christina-y-weng-md-mba-fasrshttps://www.modernretina.com/view/eichenbaum-acorns-paying-it-forward-with-christina-y-weng-md-mba-fasrs<![CDATA[From role models to open doors, Christina Y. Weng, MD, MBA, FASRS, shares insights on career development, women in ophthalmology, evolving training models, and her work as protocol chair for the DRCR Retina Network’s Protocol AO study.]]>Wed, 22 Apr 2026 22:00:00 GMTModern RetinausModern Retina Articleshttps://www.modernretina.com/view/oculis-completes-final-patient-visit-in-ocs-01-phase-3-trial-in-dmehttps://www.modernretina.com/view/oculis-completes-final-patient-visit-in-ocs-01-phase-3-trial-in-dme<![CDATA[The company noted it expects topline results in June 2026.]]>Tue, 21 Apr 2026 14:29:09 GMTModern RetinausModern Retina Articleshttps://www.modernretina.com/view/chemoplaque-therapy-for-retinoblastoma-a-potentially-novel-more-accessible-treatment-approachhttps://www.modernretina.com/view/chemoplaque-therapy-for-retinoblastoma-a-potentially-novel-more-accessible-treatment-approach<![CDATA[Early phase II results show topotecan episcleral chemoplaque offers accessible, localized retinoblastoma treatment with mixed responses, aiming to expand global eye-sparing care.]]>Mon, 20 Apr 2026 10:01:00 GMTModern RetinausModern Retina Articleshttps://www.modernretina.com/view/the-retina-tl-dr-with-dr-weng-unpacking-photobiomodulation-for-dry-amdhttps://www.modernretina.com/view/the-retina-tl-dr-with-dr-weng-unpacking-photobiomodulation-for-dry-amd<![CDATA[In the latest episode of The Retina TL;DR with Dr. Weng, host Christina Y. Weng, MD, MBA, FASRS, talks with Drs. Do, Lad, and Munk about the LIGHTSITE III trial data behind photobiomodulation and what it means for retina practice.]]>Thu, 16 Apr 2026 16:00:00 GMTModern RetinausModern Retina Articles